EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Overcoming MRSA biofilms and resistance:B The re-emergence of phage therapy and synergistic approaches

Fatemeh Roozbahani, Rouzbeh Sojoudi Masuleh, Farnaz Davari, Amirhossein Hosseinzade, Narges Asgharzadeh, Habib Hajiaghapor, Mohammad Karimbakhsh

Journal of Current Biomedical Reports · 2026

DOI: 10.66224/jcbior.7.2.346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Current Biomedical Reports, 2026. Verfasst von Fatemeh Roozbahani und 6 weiteren Autor:innen. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methicillin-resistant Staphylococcus aureus (MRSA) remains a major cause of healthcare-associated and community-acquired infections worldwide, with its multifaceted resistance mechanisms, such as N2-lactam resistance, robust biofilm formation reliant on polysaccharide intercellular adhesin and extracellular DNA, efflux pump overexpression, and target-site modifications leading to reduced susceptibility to last-line agents like linezolid and daptomycin, contributing to high recurrence rates and therapeutic failures. The emergence of vancomycin-resistant strains (VRSA) intensifies these challenges in the context of the global antimicrobial resistance crisis. Literature review of studies from recent years highlights the potent efficacy of bacteriophage-based approaches, including multi-phage cocktails, synergistic antibiotic combinations, endolysins, and CRISPR-engineered phages, in targeting planktonic cells, disrupting biofilms, and eradicating resistant subpopulations. Encouraging results from ongoing trials and compassionate-use cases underscore the safety and effectiveness of these strategies in managing chronic infections. Ultimately, phage therapy presents a precise, adaptable, and microbiota-sparing alternative that holds transformative potential for treating multidrug-resistant S. aureus infections, warranting accelerated clinical development and regulatory advancement despite persisting challenges in standardization.

Zitieren

APA

Roozbahani, F., Masuleh, R. S., Davari, F., Hosseinzade, A., Asgharzadeh, N., Hajiaghapor, H., & Karimbakhsh, M. (2026). Overcoming MRSA biofilms and resistance:B The re-emergence of phage therapy and synergistic approaches. Journal of Current Biomedical Reports. https://doi.org/10.66224/jcbior.7.2.346

Vancouver

Roozbahani F, Masuleh RS, Davari F, Hosseinzade A, Asgharzadeh N, Hajiaghapor H, et al. Overcoming MRSA biofilms and resistance:B The re-emergence of phage therapy and synergistic approaches. Journal of Current Biomedical Reports. 2026. doi:10.66224/jcbior.7.2.346

BibTeX
@article{Roozbahani2026,
  author = {Roozbahani, Fatemeh and Masuleh, Rouzbeh Sojoudi and Davari, Farnaz and Hosseinzade, Amirhossein and Asgharzadeh, Narges and Hajiaghapor, Habib and Karimbakhsh, Mohammad},
  title = {Overcoming MRSA biofilms and resistance:B The re-emergence of phage therapy and synergistic approaches},
  journal = {Journal of Current Biomedical Reports},
  year = {2026},
  doi = {10.66224/jcbior.7.2.346}
}
Kostenlos starten →